Display options
Cite
Bagnasco D, Paggiaro P, Latorre M, et al. Severe asthma: One disease and multiple definitions. World Allergy Organ J. 2021;14(11):100606doi: 10.1016/j.waojou.2021.100606.
Bagnasco, D., Paggiaro, P., Latorre, M., Folli, C., Testino, E., Bassi, A., Milanese, M., Heffler, E., Manfredi, A., Riccio, A. M., De Ferrari, L., Blasi, F., Canevari, R. F., Canonica, G. W., Passalacqua, G. (2021). Severe asthma: One disease and multiple definitions. The World Allergy Organization journal, 14(11), 100606. https://doi.org/10.1016/j.waojou.2021.100606
Bagnasco, Diego, et al. "Severe asthma: One disease and multiple definitions." The World Allergy Organization journal vol. 14,11 (2021): 100606. doi: https://doi.org/10.1016/j.waojou.2021.100606
Bagnasco D, Paggiaro P, Latorre M, Folli C, Testino E, Bassi A, Milanese M, Heffler E, Manfredi A, Riccio AM, De Ferrari L, Blasi F, Canevari RF, Canonica GW, Passalacqua G. Severe asthma: One disease and multiple definitions. World Allergy Organ J. 2021 Nov 19;14(11):100606. doi: 10.1016/j.waojou.2021.100606. eCollection 2021 Nov. PMID: 34871335; PMCID: PMC8609160.
Copy Download .nbib Format: NLM
Share it on

World Allergy Organ J. 2021 Nov 19;14(11):100606. doi: 10.1016/j.waojou.2021.100606. eCollection 2021 Nov.

Severe asthma: One disease and multiple definitions.

The World Allergy Organization journal

Diego Bagnasco, Pierluigi Paggiaro, Manuela Latorre, Chiara Folli, Elisa Testino, Arianna Bassi, Manlio Milanese, Enrico Heffler, Andrea Manfredi, Anna Maria Riccio, Laura De Ferrari, Francesco Blasi, Rikki Frank Canevari, Giorgio Walter Canonica, Giovanni Passalacqua,

Affiliations

  1. Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), IRCCS Policlinico San Martino, University of Genoa, Italy.
  2. Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Italy.
  3. Pulmonary Unit, Nuovo Ospedale Apuano, Massa, Italy.
  4. Division of Pneumology, S.Corona Hospital, Pietra Ligure, Italy.
  5. Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Milan, Rozzano, Italy.
  6. Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Milano, Italy.
  7. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy.
  8. Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.
  9. IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

PMID: 34871335 PMCID: PMC8609160 DOI: 10.1016/j.waojou.2021.100606

Abstract

INTRODUCTION: There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients.

METHODS: Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED, NICE, WHO, ATS/ERS, GINA, ENFUMOSA, and TENOR.

RESULTS: 540 patients, were extracted from the SANI database. We observed that 462 (86%) met the ATS/ERS criteria as well as the GINA criteria, 259 (48%) the U-Biopred, 222 (41%) the NICE, 125 (23%) the WHO, 313 (58%) the Enfumosa, and 251 (46%) the TENOR criteria. The mean eosinophil value were similar in the ATS/ERS, U-Biopred, and Enfumosa (528, 532 and 516 cells/mcl), higher in WHO and Tenor (567 and 570 cells/mcl) and much higher in the NICE classification (624 cells/mcl). Lung function tests resulted similarly in all groups, with WHO (67%) and ATS/ERS-GINA (73%), respectively, showing the lower and upper mean FEV1 values.

CONCLUSIONS: The present observations clearly evidence the heterogeneity in the distribution of patients when different definitions of severe asthma are used. However, the recent definition of severe asthma, provided by the GINA document, is similar to that indicated in 2014 by ATS/ERS, allowing mirror reclassification of the patients examined. This lack of homogeneity could complicate the access to biological therapies. The definition provided by the GINA document, which reflects what suggested by ATS/ERS, could partially overcome the problem.

© 2021 The Authors.

Keywords: Biological treatment; Classification; Definition; Severe asthma

Conflict of interest statement

None to declare.

References

  1. Curr Opin Allergy Clin Immunol. 2011 Apr;11(2):115-21 - PubMed
  2. Curr Opin Allergy Clin Immunol. 2018 Dec;18(6):509-518 - PubMed
  3. Thorax. 2016 Apr;71(4):339-46 - PubMed
  4. Eur Respir J. 2003 Sep;22(3):470-7 - PubMed
  5. Respir Res. 2017 Jun 26;18(1):129 - PubMed
  6. J Asthma Allergy. 2016 Mar 14;9:45-53 - PubMed
  7. Thorax. 2009 Jun;64(6):476-83 - PubMed
  8. J Allergy Clin Immunol. 2006 Mar;117(3):549-56 - PubMed
  9. Eur Respir J. 2014 Feb;43(2):343-73 - PubMed
  10. Arch Bronconeumol (Engl Ed). 2019 Mar;55(3):146-155 - PubMed
  11. Chest. 2014 Feb;145(2):219-225 - PubMed
  12. Eur Respir J. 2021 Jun 4;57(6): - PubMed
  13. Clin Ther. 2017 Nov;39(11):2216-2229 - PubMed
  14. Thorax. 2006 Aug;61(8):663-70 - PubMed
  15. Curr Opin Allergy Clin Immunol. 2019 Feb;19(1):61-67 - PubMed
  16. World Allergy Organ J. 2018 Dec 6;11(1):34 - PubMed
  17. J Allergy Clin Immunol. 2012 Aug;130(2):332-42.e10 - PubMed
  18. Curr Med Res Opin. 2017 Jan;33(1):57-65 - PubMed
  19. World Allergy Organ J. 2021 Jan 27;14(2):100509 - PubMed
  20. Allergy Asthma Proc. 2015 Nov-Dec;36(6):418-24 - PubMed
  21. J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1462-1468 - PubMed
  22. World Allergy Organ J. 2018 Jun 26;11(1):13 - PubMed
  23. Eur Respir J. 2015 Nov;46(5):1308-21 - PubMed

Publication Types